Trends in the Incidence of Parkinson Disease by Macerollo, A & Chen, J-C
Copyright 2016 American Medical Association. All rights reserved.
Letters
COMMENT&RESPONSE
Trends in the Incidence of ParkinsonDisease
To the EditorWe read with interest the article by Savica et al,1
who described an increase in the incidence rate of parkinson-
ism in the Rochester Epidemiology Project between 1976 and
2005. This finding contradicts our recently reported observa-
tion that the incidence rate of parkinsonism was lower in a
subcohort of the Rotterdam Study that was followed up
between 2000 and 2011 compared with a subcohort that was
followed up between 1990 and 2000.2 Similarly, a UK pri-
mary care study previously reported a significant decline in
Parkinson disease (PD) incidence rates between 1999 and
2009.3
Savica et al1 hypothesized that the changes observed in
the Rochester Epidemiology Project could be attributed to a
decrease in the prevalence of smoking in the second half of
the 20th century, but they were unable to test this hypoth-
esis in their cohort. Within the Rotterdam Study, we
assessed smoking habits at baseline of both subcohorts
(1990 and 2000). As expected, we observed that the age-
and sex-adjusted prevalence of current smoking was lower
across all ages (55-106 years) in the subcohort that started in
2000.2
During follow-up, incident parkinsonism was diagnosed
in 182 of 6752 persons in the subcohort that started in 1990,
and in 28 of 2440 persons in the subcohort that started in
2000. The age- and sex-adjusted incidence rate (IR) of par-
kinsonism for smokers was similar in both subcohorts
(IR, 0.63; 95% CI,0.43-0.91 in the 1990 subcohort; IR, 0.61;
95% CI, 0.27-1.44 in the 2000 subcohort). The age- and
sex-adjusted incidence rate ratio (IRR) for parkinsonism of
persons in the 2000 subcohort vs the 1990 subcohort was
0.55 (95% CI, 0.36-0.81). After additional adjustment for
smoking status, the IRR remained virtually unchanged (IRR,
0.57; 95% CI, 0.37-0.84). Unfortunately, the small number
of PD cases in the 2000 subcohort prevented PD-specific
analyses on the effect of smoking. We conclude that it is
unlikely that the decline in smoking prevalence drove a
change in the incidence of parkinsonism in the Rotterdam
Study.
The discrepant findings of the study by Savica et al1 com-
pared with previous studies, including the Rotterdam Study,
highlight the lackof insight on causality of risk factors for par-
kinsonism and PD. For smoking in particular, causality of its
inverse association with the risk for parkinsonism and PD re-
mains highly contentious,4 and the inference that the in-
crease in parkinsonism incidence in the Rochester Epidemi-
ologyProjectcanbeattributedtoadecline insmokingmayshift
focus fromother putative etiological factors. Tobetter under-
stand factors that drive differential trends in the incidence of
parkinsonism across populations, there is an urgent need for
cross-cohort collaboration, similar to recently initiated ef-
forts for dementia.5
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To the Editor In a study published in JAMA Neurology, Savica
et al1 aimed to investigate the incidence of Parkinson disease
(PD) through a retrospective study related to the 30-year pe-
riod between 1976 and 2005. Interestingly, they found a sta-
tistically significant increment of the incidence of PD inmen
70years or older. However, the incrementwas not significant
in the women’s group. This finding is in line with the previ-
ous prediction of an increase of incidence of PD in the United
States as a consequence of the reduction of smoking consid-
eredaprotective risk factor.2However,Roccaet al3didnot find
a particular trend in a previous US PD population investi-
gatedover a 15-yearperiod (1976-1990).On the contrary,Hors-
fall et al4 found a 6% decline in incidence in a UK PD popula-
tion between 1999 and 2009. However, the authors were
cautious in the interpretation of their surprising results be-
cause there is the possibility that they represented changes in
diagnosis and/or coding rather than a true decline in inci-
dence. Of note, the only epidemiological data consistent over
thesedifferent studies is thesexdifferencewith thehigher rep-
resentationofmalepatients.Theconflicting results in thesame
country aswell as in adifferent population clearly show to sci-
entists and clinicians that other potential environmental and
genetic factorsmaybe responsible for the incidenceof PDand
the explanation cannot be restricted just to smoking. Indeed,
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a number of environmental risk factors have been previously
pointed out including alcohol, elevated urate level, pesti-
cides, and head injury.5
Overall, the findingsof Savica et al1maybeexplainedwith
an improved diagnostic process in the contest of the neuro-
degenerative disease but the higher incidence is found in the
malegroupcomparedwith the femalegroup in thesamepopu-
lation, and this is completely in line with the previous litera-
ture. These data supported a genuine trend of the incidence,
which cannot be supported with the improved diagnostic
tools. However, it should be confirmed in other populations
in the European Union and United States with a systematic
investigation of related sociodemographic and geographic
factors.
What is behind the incidence of PD? This is the question
for future investigation in PD research. Detailed multicenter
assessments of thedifferent factors involved in thepathogen-
esis of neurodegeneration of PD as well as the development
of biomarkers for early diagnosis are needed to resolve the re-
maining conundrums.
Antonella Macerollo, MD
Jui-Cheng Chen, MD, PhD
Author Affiliations: Sobell Department, Institute of Neurology, University
College of London, London, England (Macerollo); School of Medicine, College of
Medicine, China Medical University, Taichung City, Taiwan (Chen); Neuroscience
Laboratory, Department of Neurology, China Medical University Hospital,
Taichung, Taiwan (Chen).
Corresponding Author: Antonella Macerollo, MD, Sobell Department, Institute
of Neurology, University College of London, 33 Queen Square, London, England
(a.macerollo@ucl.ac.uk).
Published Online:October 17, 2016. doi:10.1001/jamaneurol.2016.3850
Conflict of Interest Disclosures: None reported.
1. Savica R, Grossardt BR, Bower JH, Ahlskog JE, RoccaWA. Time trends in the
incidence of Parkinson disease. JAMA Neurol. 2016;73(8):981-989.
2. Morozova N, O’Reilly EJ, Ascherio A. Variations in gender ratios support the
connection between smoking and Parkinson’s disease. Mov Disord. 2008;23
(10):1414-1419.
3. RoccaWA, Bower JH, McDonnell SK, Peterson BJ, Maraganore DM. Time
trends in the incidence of parkinsonism inOlmsted County,Minnesota.Neurology.
2001;57(3):462-467.
4. Horsfall L, Petersen I, Walters K, Schrag A. Time trends in incidence of
Parkinson’s disease diagnosis in UK primary care. J Neurol. 2013;260(5):1351-1357.
5. Noyce AJ, Lees AJ, Schrag AE. The prediagnostic phase of Parkinson’s
disease. J Neurol Neurosurg Psychiatry. 2016;87(8):871-878.
In ReplyWeappreciate the comments expressed byDarweesh
and colleagues andbyMacerollo andChen concerning our ar-
ticle on time trends for Parkinson disease (PD) in Olmsted
County,Minnesota.1 Bothgroupsof authors challenged theat-
tributionof the increasing trend in the incidenceof PD to ade-
clining trend in cigarette smoking over time. They also called
foran international collaborative researcheffort to identify risk
and protective factors for PD.
The contrasting findings from the Rotterdam Study and
from our study suggest that the risk factors for PD may vary
across countries, by sex, and over time.2 To complicate the
landscape, 1 additional study in the United Kingdom and 1 in
Taiwan suggested a possible decline in the risk for PD.3,4 By
contrast, a second study in Taiwan showed an increase in the
incidence ratebetween2002and2009.5At thispoint,wehave
5 studies from 4 distinct countries and 3 continents showing
results in either direction.
Our study combined 2 incidence studies conducted in
the same population for 1976 to 1990 (earlier study) and 1991
to 2005 (more recent study). We have conducted extensive
studies of risk and protective factors in the earlier segment of
the incidence study (1976-1990).6 However, because of insuf-
ficient funding, we were unable to collect data on smoking,
pesticide exposure, or other risk factors in the more recent
segment of our study (1991-2005). Therefore, at this time, we
are unable to link patients with incident PD to specific risk or
protective factors over the entire 30 years of the combined
study.
We agree that the association between smoking and re-
duced risk forPDmaynotbe causal.Avoidanceof smoking ini-
tiationearly in lifeor easeof smokingcessation later in lifemay
bemarkers of a preexisting predisposition to PD (cause-effect
inversion).Therefore,otherenvironmental risk factors (eg,pes-
ticides and air,water, or soil pollutants) or behavioral risk fac-
tors (eg, alcohol, coffee, diet, exercise, or head trauma) may
bemore important. Interestingly,most of these environmen-
tal orbehavioral risk factorshaveadifferent frequencyor adif-
ferent effect in men and women.6
Our finding of a birth cohort effectmay also be of interest
in interpreting the trend. Men born in the decade from 1915
to 1924 experienced an increased risk for PD compared with
menborn inother birthdecades, bothbefore andafter.A simi-
lar trend was also observed for women, but the analyses did
not reach statistical significance.1 This birth cohort effect is
probably not in support of an effect of smoking on the trend,
but it may instead suggest exposures that took place during
intrauterine life or in early childhood (eg, infections, toxic ex-
posures, ordietarydeficiencies).1WeagreewithDarweeshand
colleagues and with Macerollo and Chen that new studies are
needed to clarify the riskorprotective factors for PD, recogniz-
ing that these factorsmayvary across populations, by sex, and
over time. We also note that it is currently difficult to obtain
funding for studies investigating epidemiologic patterns.
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To the Editor We read with interest the study by Mitsui and
colleagues1 who found decreased levels of plasma coenzyme
Q10 (CoQ10) in patients with multiple system atrophy (MSA)
regardless of the COQ2 genotype. Mutations in CoQ2 (which
encodes an essential enzyme in the biosynthetic pathway of
CoQ10) have previously been shown to be associated with
MSA.2Mitsui et al1 found a lower plasmaCoQ10 level in those
withMSA comparedwith controls (95%CI, 0.10; range, 0.02-
0.66) (P = .02). Owing to the small sample size, the reference
level of plasma CoQ2 used in the comparison had a major in-
fluence in the conclusion.
The mean (SD) plasma CoQ10 level reported in the study
was0.51 (0.22) vs0.72 (0.42) μg/mL inpatientswithMSAand
healthy controls, respectively. While the authors highlighted
that thiswascomparablewith themean(SD)serumCoQ10level
of 985.3 (939.4) nmol/L (equal to0.85 [0.81] μg/mL;n = 18) by
Kasai et al3 andmean (SD) plasmaCoQ10 level of 757 (247) nM
(equal to0.65 [0.21]μg/mL;n = 20)bySohmiyaetal4 inhealthy
Japanese controls, the sample sizes of all these studies were
rather small. We would like to draw the authors’ attention to
a recentstudyby Iwasakiandcolleagues5whoreported theme-
dianplasmaCoQ10 inhealthyJapanese individuals fromTokyo
to be 1.02 μg/mL (range, 0.93-1.11 μg/mL). This level gathered
fromamuch larger samplesize (n = 141)5wasmuchhigher than
the level in the controls in the study byMitsui et al.1 This sug-
gests that the plasma CoQ2 level in healthy controlsmay be 2
times higher than in patientswithMSA in the Japanese popu-
lation. The magnitude of this difference certainly elevates
the clinical relevance and significance of the conclusions by
Mitsui et al.1
Theauthorshaveprudently excludedpotential confound-
ing variables (such as dyslipidemia and some drugs that po-
tentially interactwithCoQ10) in their studyparticipants. Cho-
lesterol influencesCoQ10 levels by creating a conjugated form
inblood,3 but this is not an“all ornothing” interaction.Hence,
we think that measurements of the cholesterol levels in both
patientswithMSAandhealthycontrols shouldhavebeentaken
into account in the analysis using a multivariate regression
model.
IfCoQ10 levels are indeedconsistently low inpatientswith
MSA, themore challengingquestion iswhetherCoQ10supple-
mentation in patients with MSA with low CoQ2 level will be
able to improve clinical symptoms or retard disease progres-
sion. We await with great interest for future studies to ad-
dress this.
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In ReplyWe thankChao and colleagues for their comments re-
gardingour article.1 Referring to the recent article that showed
themedianplasmacoenzymeQ10 (CoQ10) level in 141healthy
Japanese individuals tobe1.02μg/mL,2whichwasmuchhigher
than that in our study (0.72 μg/mL), they suggested that the
difference in the plasma CoQ10 level between patients with
multiple system atrophy (MSA) and controls may be much
larger than previously reported. To date, 2 groups from Japan
have shown decreased plasma CoQ10 levels in patients with
MSA.1,3 As noted by Chao and colleagues, the sample sizes in
those studies were relatively small; hence, it will be impor-
tant to determine plasmaCoQ10 levels inmuch larger sample
sizes. They also mentioned that cholesterol levels should be
taken into account in evaluatingCoQ10 levels becauseplasma
cholesterol levels affect CoQ10 levels by forming a conju-
gated form.We admit that we did not include plasma choles-
terol levels in our study. However, Kasai et al3 reported that
the CoQ10 to total cholesterol ratios are significantly de-
creased in patients with MSA (mean [SD], 3.04 [1.23]) com-
paredwith those in controls (mean [SD], 5.92 [5.88]). Further-
more, 2 groups from the United Kingdom and United States
have reporteddecreasedCoQ10 levels in the cerebellumofpa-
tients with MSA.4,5 Thus, decreased CoQ10 levels in patients
withMSAare consistent findings. Although the associationof
the COQ2 V393A variant withMSA has been demonstrated in
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